SK Biopharmaceuticals Expects US$1 bln in U.S. Sales in 2029
SEOUL, July 18 (Korea Bizwire) — SK Biopharmaceuticals Co., a pharmaceutical affiliate of South Korea’s SK Group, said Tuesday that its signature anti-epilepsy treatment, Xcopri, could generate US$1 billion in sales in the United States in 2029. Xcopri, or cenobamate, is a medication for partial-onset seizures in adults discovered by SK Biopharmaceuticals and its U.S. [...]